Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Paion AG's enterprise value is $0.11 Mil.
Paion AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.81 Mil. Therefore, Paion AG's EV-to-EBITDA for today is -0.01.
The historical rank and industry rank for Paion AG's EV-to-EBITDA or its related term are showing as below:
PAIOF's EV-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.99 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Paion AG (OTCPK:PAIOF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Paion AG's share price for today is $0.07.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paion AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.978.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Paion AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Paion AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paion AG EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Paion AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Paion AG's EV-to-EBITDA falls into.
Paion AG's current Enterprise Value is $0.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paion AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paion AG (PAIOF) has a EV-to-EBITDA of -0.01 as of Jul. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Paion AG.
Is Paion AG's EV-to-EBITDA too high?
Paion AG's current EV-to-EBITDA is -0.01. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's EV-to-EBITDA compare to ZTS and NBIX?
Paion AG's EV-to-EBITDA of -0.01 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBITDA is 12.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.99, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Paion AG. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paion AG's current EV-to-EBITDA is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current EV-to-EBITDA of -0.01. The current EV-to-EBITDA is -0.01. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Paion AG (PAIOF), the current EV-to-EBITDA is -0.01 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score
Get the complete analysis for PAIOF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAIOF has been successfully added to your 
